Pelabresib not checked

Novartis · DAK539 · CPI-0610

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
7 active
7 in total · 4 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days). Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.”In the company’s words, NCT04603495 on ClinicalTrials.gov
Tested for
Primary Myelofibrosis (PMF) (2 trials), Advanced Malignancies (2 trials), Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) and 5 more
Main trialPhase 3
“A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.”In the company’s words, NCT04603495 on ClinicalTrials.gov
Other names
DAK539 · CPI-0610

Other drugs for Primary Myelofibrosis (PMF)

All 37 drugs for Primary Myelofibrosis (PMF)

Coming up4

Changes1

Last 90 days

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 23 Aug 2023 Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Phase 3Recruiting 17 May 2028 A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Phase 3Recruiting 31 Dec 2029 An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Phase 1Active, not recruiting 23 Jul 2026 Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Phase 1Recruiting 13 Nov 2026 A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
Phase 1Recruiting 9 Mar 2028 A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Phase 1Recruiting 28 Jun 2028 Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pelabresib

Following is part of Solo: you see every change to Pelabresib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in